{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:46:25Z","timestamp":1793191585607,"version":"4.5.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Nephrotic syndrome (NS) tends to be more common in patients with history of allergies. Atopic dermatitis (AD) is one of the most common allergic diseases in children. Dupilumab, a dual IL-4 and IL-13 inhibitor, has been widely used to treat AD patients. However, the efficacy and safety of Dupilumab in NS is unclear. We reported two AD patients with NS comorbidities treated with Dupilumab. The outcomes showed the good control of NS and less systemic steroids and\/or immunosuppressive agents use during the Dupilumab treatment period, accompanied by significant relief of AD symptoms. We suggest prospective pilot studies and randomized controlled trials could be carried out to validate the efficacy and safety of Dupilumab in the treatment of NS patients.<\/jats:p>","DOI":"10.3389\/fmed.2022.813313","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T06:42:36Z","timestamp":1651214556000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: The Application of Dupilumab in Atopic Dermatitis Children Complicated With Nephrotic Syndrome"],"prefix":"10.3389","volume":"9","author":[{"given":"Ya-Qi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ru","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Fei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamapediatrics.2017.0556","article-title":"Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood","volume":"171","author":"Roduit","year":"2017","journal-title":"JAMA Pediatr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/all.12874","article-title":"An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011","volume":"71","author":"Wang","year":"2016","journal-title":"Allergy."},{"key":"B3","doi-asserted-by":"publisher","first-page":"29751","DOI":"10.1038\/srep29751","article-title":"Prevalence of atopic dermatitis in Chinese children aged 1-7 ys","volume":"6","author":"Guo","year":"2016","journal-title":"Sci Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3389\/fped.2016.00039","article-title":"Ethnic differences in childhood nephrotic syndrome","volume":"4","author":"Chanchlani","year":"2016","journal-title":"Front Pediatr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s10157-010-0330-z","article-title":"Th2 cells predominate in idiopathic steroid-sensitive nephrotic syndrome","volume":"14","author":"Kanai","year":"2010","journal-title":"Clin Exp Nephrol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.21037\/tau-20-665","article-title":"A review of nephrotic syndrome and atopic diseases in children","volume":"10","author":"Zheng","year":"2021","journal-title":"Transl Androl Urol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.2188\/jea.JE20140167","article-title":"Occurrence of common allergic diseases in children with idiopathic nephrotic syndrome","volume":"25","author":"Wei","year":"2015","journal-title":"J Epidemiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/bjd.19613","article-title":"Long-term safety of dupilumab in children","volume":"184","author":"Sibbald","year":"2021","journal-title":"Br J Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/bjd.19460","article-title":"Dupilumab provides favourable long-term safety and efficacy in children aged \u22656\u2013 <12 years with uncontrolled severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study","volume":"184","author":"Cork","year":"2021","journal-title":"Br J Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6\u201311 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/jdv.16928","article-title":"A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy","volume":"35","author":"Paller","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40272-020-00387-2","article-title":"Dupilumab to treat type 2 inflammatory diseases in children and adolescents","volume":"22","author":"Licari","year":"2020","journal-title":"Paediatr Drugs."},{"key":"B13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1080\/20469047.2017.1374003","article-title":"Nephrotic syndrome in infants and children: pathophysiology and management","volume":"37","author":"Downie","year":"2017","journal-title":"Paediatr Int Child Health."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1007\/s00467-014-2835-2","article-title":"Increased risk of idiopathic nephrotic syndrome in children with atopic dermatitis","volume":"29","author":"Wei","year":"2014","journal-title":"Pediatr Nephrol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1136\/adc.56.7.509","article-title":"Steroid-responsive and nephrotic syndrome and allergy: clinical studies","volume":"56","author":"Meadow","year":"1981","journal-title":"Arch Dis Child."},{"key":"B16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00467-008-1003-y","article-title":"Polymorphisms in interleukin-4-related genes in patients with minimal change nephrotic syndrome","volume":"24","author":"Ikeuchi","year":"2009","journal-title":"Pediatr Nephrol."},{"key":"B17","first-page":"83","article-title":"Type 1\/type 2 cytokine serum levels and role of interleukin-18 in children with steroid-sensitive nephrotic syndrome","volume":"6","author":"Shalaby","year":"2013","journal-title":"Arab J Nephrol Transplant."},{"key":"B18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/tropej\/fmu040","article-title":"Serum immunoglobulin E and interleukin-13 levels in children with idiopathic nephrotic syndrome","volume":"60","author":"Mishra","year":"2014","journal-title":"J Trop Pediatr."},{"key":"B19","first-page":"298","article-title":"T helper 1 and T helper 2 cytokines in atopic children with steroid-sensitive nephrotic syndrome","volume":"9","author":"Youssef","year":"2015","journal-title":"Iran J Kidney Dis."},{"key":"B20","first-page":"219","volume":"6","author":"Fanconi","year":"1951","journal-title":"Helv Paediatr Acta."},{"key":"B21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nri3831","article-title":"Type 2 cytokines: mechanisms and therapeutic strategies","volume":"15","author":"Wynn","year":"2015","journal-title":"Nat Rev Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00467-004-1438-8","article-title":"Atopy, serum IgE, and interleukin-13 in steroid-responsive nephrotic syndrome","volume":"19","author":"Cheung","year":"2004","journal-title":"Pediatr Nephrol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1681\/ASN.2006070710","article-title":"Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats","volume":"18","author":"Lai","year":"2007","journal-title":"J Am Soc Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrneph.2012.115","article-title":"Childhood nephrotic syndrome\u2013current and future therapies","volume":"8","author":"Greenbaum","year":"2012","journal-title":"Nat Rev Nephrol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/ckj\/sfaa265","article-title":"Multidimensional inflammatory and immunological endotypes of idiopathic focal segmental glomerulosclerosis and their association with treatment outcomes","volume":"14","author":"Roca","year":"2020","journal-title":"Clin Kidney J."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.813313\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T06:42:43Z","timestamp":1651214563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.813313\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":25,"alternative-id":["10.3389\/fmed.2022.813313"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.813313","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"article-number":"813313"}}